GILD Stock News 80.30 05/13/2014 16:05:08 Gilead Sciences (G

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 80.30 $GILD

Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14
Business Wire - 4 mins ago
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas.

Gilead Shows More Pipeline Progress - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 19 mins ago
Gilead (GILD) announced encouraging results from a study on the combination of Ranexa and Multaq.

Midday Glance: Biotechnology companies
AP - Tue May 13, 12:43PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

3 Reasons to Buy the Market's Biggest Health Insurer
Dan Carroll, The Motley Fool - Motley Fool - Tue May 13, 11:05AM CDT
No change has hit the health care sector recently like Obamacare. The new health law has transformed many parts of America's insurance landscape, but one thing's remained the same: UnitedHealth Group 's the market's largest insurer by subscribers....

PDL BioPharma Misses on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 13, 10:40AM CDT
PDL BioPharma (PDLI) posted first-quarter 2014 earnings of 48 cents per share, below the Zacks Consensus Estimate of 50 cents.

Global Pulmonary Drug Delivery Market & Clinical Pipeline Insight 2014
M2 - Tue May 13, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qg8fk3/pulmonary_drug) has announced the addition of the "Pulmonary Drug Delivery Market & Clinical Pipeline Insight" report to their offering. The demand for new and innovative drug delivery systems has been on a rising trend with the pharmaceutical companies concentrating on developing innovative methods for this area. It is the result of these continued efforts, which have led to the ever rising popularity of pulmonary drug delivery methods across the globe. Pulmonary drug delivery system uses the respiratory tract to deliver drugs into the lungs in order to treat diseases such as asthma, COPD and cystic fibrosis. This market has been attracting significant investments by the pharma companies with relation to development of novel treatment methods. The system of targeted drug delivery to the lungs has become one of the most popularly investigated systemic or local drug delivery approach. With the passing of time, the drug delivery systems specifically being used for the treatment of pulmonary diseases have increased due to their potential for localized topical therapy in the lungs. One of the major advantages offered by this route is that it is possible to deposit drugs more specifically at the site with high concentrations within the diseased lung. This helps in reducing the overall amount of drug given to patients, and also increases local drug activity while simultaneously reducing systemic the side effects and first-pass metabolism. The pulmonary technology offers an exclusive and inventive alternative for drug delivery as it allows for a systemic delivery of large and small molecule drugs through inhalation into the lungs. This mode of drug delivery have helped in reducing the adverse effects of low solubility and absorption of drugs which are present in the other therapies through the oral, intravenous and injection routes. Owing to the rising incidences of respiratory tract related diseases like chronic obstructive pulmonary disease (COPD), asthma etc, coupled with the advancements made in the technology of drug delivery, the global market for pulmonary drug delivery system is likely to grow at a rapid rate. Additionally, the pharma companies have recently recognized the future potential of inhaled therapies and the extended application beyond asthma and COPD, and therefore, have been working towards tapping the opportunities for growth through product differentiation. Pulmonary Drug Delivery Market & Clinical Pipeline Analysis Report Highlights: - Pulmonary Drug Delivery Market Overview - Favorable Market Drivers & Key Issues to be Discussed - Pulmonary Drug Clinical Pipeline by Phase, Disease & Country - Pulmonary Drug Profiles in Report: 566 - Majority of Pulmonary Drugs in Preclinical Phase: 79 - Number of Marketed Pulmonary Drugs: 63 - Number of Discontinued & Suspended Drug Profiles: 283 Key Topics Covered: 1. Introduction to Pulmonary Drug Delivery 2. Pulmonary Drug Delivery Mechanism 3. Why Need for Pulmonary Drug Delivery? 4. Pulmonary Drug Delivery Market Outlook 5. Pulmonary Drug Delivery Market Dynamics 6. Future of Pulmonary Drug Delivery Market 7. Pulmonary Drug Clinical Insight by Phase, Country & Target Indication 8. Marketed Pulmonary Drug Profiles 9. Suspended & Discontinued Pulmonary Drug Profiles 10. Competitive Landscape - Allergan Inc. (MAP Pharmaceuticals) - AstraZeneca (Pearl Therapeutics) - Bayer HealthCare Pharmaceuticals - Boehringer Ingelheim - Gilead Sciences - Merck - Novartis - Pfizer - Teva Pharmaceutical (Microdose Therapeutx) - Vectura Group For more information visit http://www.researchandmarkets.com/research/qg...onary_drug

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023
M2 - Tue May 13, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fs46lc/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. The pharmaceutical giant Novartis benefits a bit more from its recently announced partnership with Glaxo Smith Kline. The two drug makers will combine and among other transactions, Glaxo will buy Novartis's vaccine business and Novartis will gain Glaxo's oncology drug pipeline. Revenues of major pharma companies are broke out by these therapeutic areas in the report, Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023. Novartis has about 1/3 of its pharmaceutical revenues coming from oncology products. Thus it certainly makes sense to build that area, according to Kalorama's report. Novartis is currently number 2 in the world for cancer therapies behind Roche. The firm does not think that Novartis rises in market share from the deal, but it does believe it will certainly strengthen its position and maintain its wide distance from the 3rd competitor in the market. Although Kalorama also thinks the move benefits Glaxo Smith Kline, there could be less advantages for the company in the deal than for Novartis. Novartis will keep influenza vaccines, as part of the deal. This could work out to be highly beneficial, vaccines is a competitive area. The positions of companies do shift somewhat from year to year with vacillations in flu vaccines and other specific products, although for the past few years, Glaxo has led the market and Novartis has trailed at a distance. Furthermore, in pediatric vaccines GSK is also a major contributor and leader and solidifying this position is good but is not really helpful in the overall picture. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 estimates current sales for major pharmaceutical companies, breaks out revenue by therapeutic area and discusses general trends in the industry. Market watchers can use the report to understand developments in greater context than news media can provide. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 Top 25 Companies Mentioned - Abbvie, inc. - Actavis - Amgen, inc. - Astellas - Astra Zeneca plc - Baxter international - Bayer AG - Boehringer Ingelheim gmbh - Bristol-myers Squibb Company - Daiichi Sankyo - Eli Lilly and Company - Gilead Sciences - Glaxosmithkline PLC - Johnson & johnson - Merck & Co., inc. - Merck KGAA - Mylan - Novartis AG - Novo nordisk - Otsuka Pharmaceutical - Pfizer, inc. - Roche ltd. - Sanofi - Takeda Pharmaceutical co., LTD - Teva Pharmaceutical Industries, Ltd. For more information visit http://www.researchandmarkets.com/research/fs46lc/top_25

Repros' Q1 Loss In Line with Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 13, 10:00AM CDT
Repros Therapeutics (RPRX) reported first quarter 2014 loss of 37 cents per share.

Halozyme's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 13, 9:54AM CDT
Halozyme Therapeutics, Inc.'s (HALO) loss widens in the first quarter of 2014.

Early Glance: Biotechnology companies
AP - Tue May 13, 9:41AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Osiris Therapeutics Q1 Loss Narrower-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 13, 8:00AM CDT
Osiris Therapeutics (OSIR) reported a significant increase in first quarter 2014 revenues.

Tesaro, Inc. (TSRO) Looks Strong as Stock Rallies 21% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 13, 7:44AM CDT
Tesaro, Inc. (TSRO) was a big mover last session, as its shares surge 21% on the day.

Final Glance: Biotechnology companies
AP - Mon May 12, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:

Illumina Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 1:10PM CDT
On May 10, we upgraded Illumina Inc. (ILMN) to a Zacks Rank #1 (Strong Buy).

Amgen-AstraZeneca Psoriasis Drug Scores - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 12:50PM CDT
Amgen (AMGN) and AstraZeneca's (AZN) brodalumab achieved the primary and secondary endpoints in a late-stage study.

Loss Widens at Achillion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 10:40AM CDT
Achillion reported a first quarter 2014 loss of 17 cents per share.

Mallinckrodt Earnings Beat, Shares Dip on Low Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 10:30AM CDT
Mallinckrodt's (MNK) shares have been moving downwards following the company's revenue miss.

Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.

Shares Continue to fall on Emergent BioSolutions' Wider Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 9:10AM CDT
Shares of Emergent BioSolutions (EBS) have been on the way down since it reported wider first quarter 2014 loss.

RadNet Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 9:05AM CDT
RadNet (RDNT) recorded an earnings surprise in 3 of its last 4 quarters, with an average beat of 133.96%.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 101

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 10

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
2GenPen's Patent Push: Transforming Credit Analysis

Updated Category News Views 111

Changing the Game in Credit Analysis When you hear about a company snagging a patent, it's usually a big whoop-de-do; but 2GenPen's latest achievement is making some serious waves. This isn't some 'pat-yourself-on-the-back' sort of news – it's got teeth in the world of finance. These folks just locked down their second U.S. patent, number 12,784,096, and it's all about...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 49

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 19

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 234

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 0

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
LONGWELL's New Axial Fan Selection Guide Unveiled

Updated Category News Views 75

LONGWELL's New Fan Brochure Shakes Up Data Center Cooling Alright, let's cut to the chase. LONGWELL, the folks out in Ningbo who live and breathe HVACR and industrial fans, have dropped a new tool that’s going to have OEM engineers raising a glass. This twelve-page axial fan selection guide is a stroke of genius—or at least that's what those of us who've braved the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 162

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles